CD274 and non-small cell lung carcinoma: The approval of the PD-L1 IHC 28-8 pharmDx as a companion diagnostic intended for use in the detection of PD-L1 protein to identify NSCLC patients for treatment with nivolumab in combination with ipilimumab was granted in May 2020 (67).